CSL announced Tuesday that Chief Executive Paul McKenzie is stepping down, with Gordon Naylor stepping in as interim CEO and managing director beginning Feb. 11. McKenzie, who came aboard as chief operating officer in 2019, moved up to the CEO post in March 2023. During his tenure, CSL rolled out new treatments, including Hemgenix, its gene therapy for haemophilia B. Naylor, previously finance chief and head of the Seqirus vaccines division, took a board seat in December. CSL shares dropped 4.98% on Tuesday, underperforming the S&P/ASX 200, which edged just 0.03% lower to 8,867.4 points despite spending much of the session in positive territory. The company filed news of its leadership shakeup at 4:05 p.m., after the bell. Naylor, together with CFO Ken Lim and other top brass, will present CSL’s half-year results on Wednesday.